Safety	safety	O	O
and	and	O	O
side-effects	side-effects	O	O
of	of	O	O
alprazolam	alprazolam	S_chemical	O
.	.	O	O

Controlled	controlled	O	O
study	study	O	O
in	in	O	O
agoraphobia	agoraphobia	O	S_disease
with	with	O	O
panic	panic	O	B_disease
disorder	disorder	O	I_disease
.	.	O	O

BACKGROUND	background	O	O
:	:	O	O
The	the	O	O
widespread	widespread	O	O
use	use	O	O
of	of	O	O
benzodiazepines	benzodiazepines	S_chemical	O
has	has	O	O
led	led	O	O
to	to	O	O
increasing	increasing	O	O
recognition	recognition	O	O
of	of	O	O
their	their	O	O
unwanted	unwanted	O	O
effects	effects	O	O
.	.	O	O

The	the	O	O
efficacy	efficacy	O	O
of	of	O	O
alprazolam	alprazolam	S_chemical	O
and	and	O	O
placebo	placebo	O	O
in	in	O	O
panic	panic	O	B_disease
disorder	disorder	O	I_disease
with	with	O	O
agoraphobia	agoraphobia	O	S_disease
,	,	O	O
and	and	O	O
the	the	O	O
side-effect	side-effect	O	O
and	and	O	O
adverse	adverse	O	O
effect	effect	O	O
profiles	profiles	O	O
of	of	O	O
both	both	O	O
drug	drug	O	O
groups	groups	O	O
were	were	O	O
measured	measured	O	O
.	.	O	O

METHOD	method	O	O
:	:	O	O
In	in	O	O
London	london	O	O
and	and	O	O
Toronto	toronto	O	O
154	154	O	O
patients	patients	O	O
who	who	O	O
met	met	O	O
DSM-III	dsm-iii	O	O
criteria	criteria	O	O
for	for	O	O
panic	panic	O	B_disease
disorder	disorder	O	I_disease
with	with	O	O
agoraphobia	agoraphobia	O	S_disease
were	were	O	O
randomised	randomised	O	O
to	to	O	O
alprazolam	alprazolam	S_chemical	O
or	or	O	O
placebo	placebo	O	O
.	.	O	O

Subjects	subjects	O	O
in	in	O	O
each	each	O	O
drug	drug	O	O
group	group	O	O
also	also	O	O
received	received	O	O
either	either	O	O
exposure	exposure	O	O
or	or	O	O
relaxation	relaxation	O	O
.	.	O	O

Treatment	treatment	O	O
was	was	O	O
from	from	O	O
weeks	weeks	O	O
0	0	O	O
to	to	O	O
8	8	O	O
and	and	O	O
was	was	O	O
then	then	O	O
tapered	tapered	O	O
from	from	O	O
weeks	weeks	O	O
8	8	O	O
to	to	O	O
16	16	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
Mean	mean	O	O
alprazolam	alprazolam	S_chemical	O
dose	dose	O	O
was	was	O	O
5	5	O	O
mg	mg	O	O
daily	daily	O	O
.	.	O	O

Compared	compared	O	O
with	with	O	O
placebo	placebo	O	O
subjects	subjects	O	O
,	,	O	O
alprazolam	alprazolam	S_chemical	O
patients	patients	O	O
developed	developed	O	O
more	more	O	O
adverse	adverse	O	O
reactions	reactions	O	O
(	(	O	O
21	21	O	O
%	%	O	O
v.	v.	O	O
0	0	O	O
%	%	O	O
)	)	O	O
of	of	O	O
depression	depression	O	S_disease
,	,	O	O
enuresis	enuresis	O	O
,	,	O	O
disinhibition	disinhibition	O	O
and	and	O	O
aggression	aggression	O	S_disease
;	;	O	O
and	and	O	O
more	more	O	O
side-effects	side-effects	O	O
,	,	O	O
particularly	particularly	O	O
sedation	sedation	O	O
,	,	O	O
irritability	irritability	O	S_disease
,	,	O	O
impaired	impaired	O	O
memory	memory	O	O
,	,	O	O
weight	weight	O	B_disease
loss	loss	O	I_disease
and	and	O	O
ataxia	ataxia	O	S_disease
.	.	O	O

Side-effects	side-effects	O	O
tended	tended	O	O
to	to	O	O
diminish	diminish	O	O
during	during	O	O
treatment	treatment	O	O
but	but	O	O
remained	remained	O	O
significant	significant	O	O
at	at	O	O
week	week	O	O
8	8	O	O
.	.	O	O

Despite	despite	O	O
this	this	O	O
,	,	O	O
the	the	O	O
drop-out	drop-out	O	O
rate	rate	O	O
was	was	O	O
low	low	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
Alprazolam	alprazolam	S_chemical	O
caused	caused	O	O
side-effects	side-effects	O	O
and	and	O	O
adverse	adverse	O	O
effects	effects	O	O
during	during	O	O
treatment	treatment	O	O
but	but	O	O
many	many	O	O
patients	patients	O	O
were	were	O	O
willing	willing	O	O
to	to	O	O
accept	accept	O	O
these	these	O	O
.	.	O	O

